| Literature DB >> 34684741 |
Mahesh Attimarad1, Katharigatta N Venugopala1,2, Bandar E Al-Dhubiab1, Rafea Elamin Elgack Elgorashe3, Sheeba Shafi4.
Abstract
Three rapid, accurate, and ecofriendly processed spectrophotometric methods were validated for the concurrent quantification of remogliflozin (RGE) and vildagliptin (VGN) from formulations using water as dilution solvent. The three methods developed were based on the calculation of the peak height of the first derivative absorption spectra at zero-crossing points, the peak amplitude difference at selected wavelengths of the peak and valley of the ratio spectra, and the peak height of the ratio first derivative spectra. All three methods were validated adapting the ICH regulations. Both the analytes showed a worthy linearity in the concentration of 1 to 60 µg/mL and 2 to 90 µg/mL for VGN and RGE, respectively, with an exceptional regression coefficient (r2 ≥ 0.999). The developed methods demonstrated an excellent recovery (98.00% to 102%), a lower percent relative standard deviation, and a relative error (less than ±2%), confirming the specificity, precision, and accuracy of the proposed methods. In addition, validated spectrophotometric methods were commendably employed for the simultaneous determination of VGN and RGE from solutions prepared in the laboratory and the formulation. Hence, these methods can be utilized for the routine quality control study of the pharmaceutical preparations of VGN and RGE in pharmaceutical industries and laboratories. The ecofriendly nature of the anticipated spectrophotometric procedures was confirmed by the evaluation of the greenness profile by a semi-quantitative method and the quantitative and qualitative green analytical procedure index (GAPI) method.Entities:
Keywords: determination; ecofriendly; formulation; ratio derivative spectrophotometry; remogliflozin; vildagliptin
Mesh:
Substances:
Year: 2021 PMID: 34684741 PMCID: PMC8537597 DOI: 10.3390/molecules26206160
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chemical structure of remogliflozin etabonate (A) and vildagliptin (B).
Figure 2(A) Normal spectra of RGE, VGN, and a mixture. (B) First derivative spectra of RGE, VGN, and the mixture. Zero-crossings of RGE (a), zero-crossings of VGN (c), and the same amplitude points (b and d). (C) First derivative spectra of VGN 2 to 60 µg/mL with the RGE spectrum. (D) First derivative spectra of RGE 5 to 90 µg/mL with the VGN spectrum.
Figure 3(A) Ratio absorption spectra of RGE (2 to 75 µg/mL) using a 5 µg/mL spectrum of VGN. (B) Ratio absorption spectra of pure RGE and a mixture. (C) Ratio absorption spectra of VGN (1 to 50 µg/mL) using a 5 µg/mL spectrum of RGE. (D) Ratio absorption spectra of pure VGN and a mixture.
Figure 4(A) Ratio first derivative spectra of RGE (2 to 75 µg/mL). (B) Ratio first derivative spectra of pure RGE and a mixture. (C) Ratio first derivative spectra of VGN (1 to 50 µg/mL). (D) Ratio first derivative spectra of pure VGN and a mixture.
Validation parameter results of the proposed spectroscopic methods for the simultaneous determination of VGN and RGE.
| Validation | Remogliflozin | Vildagliptin | ||||
|---|---|---|---|---|---|---|
| FDS | RDS | RFD | FDS | RDS | RFD | |
| Wavelength (nm) | 287.7 | 230.3–251.4 | 237.2 | 213.7 | 207.2–230.6 | 213.7 |
| Linearity range (µg/mL) | 5–90 | 2–75 | 2–75 | 2–60 | 1–50 | 1–50 |
| Slope | 0.0031 | 1.328 | 1.226 | 0.012 | 0.0983 | 0.0920 |
| Intercept | −0.0051 | −1.221 | −0.884 | 0.008 | 0.2489 | 0.0841 |
| Regression coefficient (r2) | 0.9997 | 0.9998 | 0.9997 | 0.9996 | 0.9990 | 0.9994 |
| LOD (µg/mL) | 1.361 | 0.583 | 0.408 | 0.484 | 0.272 | 0.176 |
| LOQ (µg/mL) | 4.126 | 1.768 | 1.236 | 1.469 | 0.827 | 0.535 |
| Accuracy (Mean % ± SD) | 99.41 ± 1.170 | 99.13 ± 0.665 | 100.82 ± 0.910 | 99.52 ± 0.834 | 99.88 ± 1.655 | 101.07 ± 0.729 |
| Precision (%RSD) | ||||||
| Intraday | 0.730 | 1.026 | 1.843 | 0.610 | 0.871 | 0.728 |
| Interday | 0.937 | 1.383 | 0.611 | 1.748 | 0.725 | 1.287 |
Assay results of the laboratory mixed solutions of VGN and RGE.
| Laboratory Prepared Mixture (µg/mL) | Remogliflozin (% Recovery) | Vildagliptin (% Recovery) | |||||
|---|---|---|---|---|---|---|---|
| RGE | VGN | FDS | RDS | RFD | FDS | RDS | RFD |
| 10 | 50.00 | 99.20 | 101.60 | 98.50 | 98.30 | 98.22 | 101.04 |
| 40 | 50.00 | 97.93 | 100.70 | 99.43 | 98.58 | 99.06 | 100.78 |
| 40 | 5.00 | 100.30 | 96.48 | 100.20 | 98.60 | 99.40 | 99.80 |
| 70 | 5.00 | 99.24 | 98.06 | 99.03 | 101.20 | 100.40 | 98.60 |
| 70 | 25.00 | 100.67 | 98.73 | 98.21 | 99.24 | 99.04 | 101.36 |
| Across Mean | 99.47 | 99.11 | 99.07 | 99.18 | 99.27 | 100.32 | |
| SD | 0.964 | 1.840 | 0.702 | 1.054 | 0.705 | 1.004 | |
Assay results of the formulation and the standard addition method results.
| Formulation Concentration | Remogliflozin (Mean %± SD) | Vildagliptin (Mean % ± SD) | |||||
|---|---|---|---|---|---|---|---|
| RGE | VGN | FDS | RDS | RFD | FDS | RDS | RFD |
| 100 mg | 50 mg | 99.42 ± 0.985 | 99.62 ± 0.788 | 99.10 ± 0.76 | 99.77 ± 1.563 | 100.04 ± 1.384 | 100.19 ± 0.797 |
| Standard Addition Method | |||||||
| Amount Added (µg/mL) | Remogliflozin (% Recovery) | Vildagliptin (% Recovery) | |||||
| 10 µg/mL | 5 | 98.70 | 100.70 | 98.30 | 99.20 | 100.40 | 99.80 |
| 20 µg/mL | 10 | 100.95 | 98.85 | 99.05 | 101.90 | 98.20 | 101.30 |
| 30 µg/mL | 15 | 96.47 | 99.30 | 100.23 | 98.20 | 101.53 | 99.47 |
| Across Mean | 98.71 | 99.62 | 99.19 | 99.77 | 100.04 | 100.19 | |
| %RSD | 1.830 | 0.788 | 0.796 | 1.563 | 1.384 | 0.797 | |
Figure 5(A) Greenness evaluation results of the proposed method by Raynie et al.’s method [33]. (B) The GAPI method.
The GAPI evaluation results for the spectrophotometric methods.
| Category | UV Spectrophotometric Methods |
|---|---|
| Sample Preparation | |
| Collection (1) | In-line |
| Preservation (2) | Nil |
| Transport (3) | Nil |
| Storage (4) | Nil |
| Type of method: direct or indirect (5) | Direct (no sample preparation) |
| Scale of extraction (6) | Nil |
| Solvents/reagents used (7) | Green Solvents |
| Additional treatments (8) | Nil |
| Reagent and solvents | |
| Amount (9) | <10 mL |
| Health hazard (10) | Ethanol, slightly toxic and irritant NFPA score 1 |
| Safety hazard (11) | Ethanol, instability score 0, flammability score 1, no special hazard |
| Instrumentation | |
| Energy (12) | ≤0.1 kWh/sample |
| Occupational hazard (13) | Hermetic sealing of the analytical procedure |
| Waste (14) | 1–10 mL |
| Waste treatment (15) | No treatment |
| Quantification | Yes |